

Research article

Open Access

Recognition of secretory proteins in *Escherichia coli* requires signals in addition to the signal sequence and slow folding

Ipsita Mallik, Margaret A Smith and Ann M Flower*

Address: Department of Microbiology and Immunology, University of North Dakota School of Medicine and Health Sciences, Grand Forks, ND 58202-9037

E-mail: Ipsita Mallik - ipsita123@yahoo.com; Margaret A Smith - masmith@medicine.nodak.edu; Ann M Flower* - aflower@medicine.nodak.edu

*Corresponding author

Published: 11 November 2002

Received: 8 October 2002

BMC Microbiology 2002, **2**:32

Accepted: 11 November 2002

This article is available from: <http://www.biomedcentral.com/1471-2180/2/32>

© 2002 Mallik et al; licensee BioMed Central Ltd. This article is published in Open Access: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Background: The Sec-dependent protein export apparatus of *Escherichia coli* is very efficient at correctly identifying proteins to be exported from the cytoplasm. Even bacterial strains that carry *prl* mutations, which allow export of signal sequence-defective precursors, accurately differentiate between cytoplasmic and mutant secretory proteins. It was proposed previously that the basis for this precise discrimination is the slow folding rate of secretory proteins, resulting in binding by the secretory chaperone, SecB, and subsequent targeting to translocase. Based on this proposal, we hypothesized that a cytoplasmic protein containing a mutation that slows its rate of folding would be recognized by SecB and therefore targeted to the Sec pathway. In a *Prl* suppressor strain the mutant protein would be exported to the periplasm due to loss of ability to reject non-secretory proteins from the pathway.

Results: In the current work, we tested this hypothesis using a mutant form of λ repressor that folds slowly. No export of the mutant protein was observed, even in a *prl* strain. We then examined binding of the mutant λ repressor to SecB. We did not observe interaction by either of two assays, indicating that slow folding is not sufficient for SecB binding and targeting to translocase.

Conclusions: These results strongly suggest that to be targeted to the export pathway, secretory proteins contain signals in addition to the canonical signal sequence and the rate of folding.

Background

The Sec-dependent protein export pathway of *Escherichia coli* is responsible for translocation of secretory proteins across the inner membrane to final destinations in the periplasm or outer membrane. Secretory proteins, also called preproteins, are synthesized with a cleavable amino terminal signal sequence that functions both to slow folding of the preprotein and to aid in recognition of the secretory protein by export factors. Export of many, but not

all, secretory proteins is dependent on interaction with SecB, a cytoplasmic chaperone that maintains the preprotein in a loosely folded conformation competent for translocation. Both SecB and the preprotein provide binding sites for SecA, a peripheral membrane ATPase. SecA targets the preprotein to the membranous translocase complex composed of SecY, SecE, SecG, SecD, SecF, and YajC. Formation of the complete translocase complex promotes an ATP binding and hydrolysis cycle by SecA that results in

segmental translocation of the secretory protein across the membrane [1–4].

The signal sequence is crucial for efficient translocation; mutations in the signal sequence significantly reduce export of the preprotein and complete deletions of the signal sequence eliminate essentially all export [5–8]. Selection for extragenic suppressors of such export defective preproteins led to the identification of the *prl* alleles of *secY* (*prlA*), *secE* (*prlG*), *secA* (*prlD*), and more recently *secG* (*prlH*) [6,9–11]. Early hypotheses predicted that the P_{rl} suppressors function by expanded or altered interactions with signal sequences, facilitating recognition of mutant as well as wild type signal sequences [6].

More recent observations support an alternative mechanism of action for the P_{rlA}/SecY and P_{rlG}/SecE suppressors [8,12]. First, P_{rlA}/G-mediated suppression does not exhibit allele specificity; all *prlA* and all *prlG* alleles that have been examined suppress all signal sequence mutations, implying that suppression is not due to a specific altered interaction that allows recognition of a mutant signal sequence [8,12]. Furthermore, all of the *prlA* and *prlG* alleles suppress complete deletions of the signal sequence, suggesting that an interaction between the signal sequence and the P_{rl} suppressor is not necessary for suppression or even for export [5,8,13]. Based on these observations, it was proposed that the P_{rlA} and P_{rlG} suppressors do not function through altered interactions with signal sequences, but rather by loss of recognition [8,12]. The wild type SecE and SecY proteins are thought to function in concert to proofread the signal sequence of secretory proteins, rejecting defective precursors from the export pathway. The P_{rlA} (SecY) and P_{rlG} (SecE) suppressors are compromised in their ability to proofread, allowing export of proteins with mutations, or even complete deletions, of the signal sequence.

This proofreading model predicts that the critical step for translocation of a signal sequence-defective secretory protein is recognition by SecB and subsequent presentation to SecE/Y. SecB binds portions of the mature secretory protein [14–18], and SecA would bind to the SecB-precursor complex by virtue of its ability to bind SecB [19,20] as well as the preprotein [21–23]. Thus, SecA-mediated targeting of the preprotein to translocase would occur. In a wild type cell, the mutant precursor would be rejected at this point by SecY/E, but in a P_{rlA} or P_{rlG} suppressor strain, rejection would not occur and the mutant secretory protein would be exported.

In fact, all of the P_{rlA} and P_{rlG} suppressors are completely dependent on functional SecB for manifestation of suppressor activity [5,8]. Even certain proteins that are not normally SecB-dependent for translocation become SecB-

dependent when they contain a signal sequence mutation and are exported via the suppressor pathway. For example, PhoA is normally exported independent of SecB. Deletion of the signal sequence from *phoA* severely compromises export; export is restored in a *prlA* suppressor strain. However, this suppression is dependent on SecB [5]. Therefore, there are characteristics of the mature portion of PhoA that promote recognition by SecB, and this recognition is essential for P_{rlA}-mediated suppression.

Although *prlA* and *prlG* strains export secretory proteins that completely lack a signal sequence, there is no evidence of export of any cytoplasmic proteins in a *prl* suppressor strain [13]. That is, proteins that are supposed to remain in the cytoplasm are not mislocalized to the periplasm. It has been suggested that perhaps cytoplasmic proteins are not exported in *prl* suppressor strains because they fold rapidly and escape recognition by SecB, while secretory proteins, even those lacking a signal sequence, fold more slowly, allowing time for SecB recognition and binding [5,13]. SecB binds to a variety of unfolded proteins in vitro [24,25], although binding appears to be more selective in vivo [26]. This selectivity may be based on the slower folding characteristics of secretory proteins.

Therefore, we proposed previously that if a cytoplasmic protein contains a mutation that slows its rate of folding, SecB will recognize and bind to that mutant protein. Binding of SecB would result in targeting of the unfolded protein to the translocation apparatus. According to the proofreading model, in a wild type strain, SecE and SecY would reject the unfolded protein due to lack of a signal sequence. In a P_{rl} suppressor strain, however, the proofreading function would be compromised and the mutant protein would be exported [8]. In the experiments described here, we tested this hypothesis by examining the export of such a cytoplasmic protein with a folding mutation. The results indicate that slow folding is not sufficient for SecB binding and subsequent targeting to translocase and further, that secretory proteins contain targeting information in addition to the signal sequence and the folding kinetics.

Results and Discussion

To test the hypothesis that a cytoplasmic protein containing a mutation that slowed its folding would be exported in a P_{rl} suppressor strain, a well characterized cytoplasmic protein was obtained. The protein of choice was the amino terminal portion of the λ repressor protein, a 92 residue domain that folds into a stable, predominantly α -helical structure [27]. Folding studies were performed at a pH and ionic strength similar to physiological conditions and the folding parameters were predicted to approximate the in vivo situation. The wild type protein (N^{102LT}) is




Figure 1
Immunodetection of λ repressor fragments in bacterial fractions LA57 indicates the slow folding λ repressor, LA57-N^{102LT}, while wt refers to the wild type λ repressor, N^{102LT}. The strains used were either wild type *secY/prlA* or *prlA4* as indicated. The individual lanes are as follows: M – purified N^{102LT} used as a molecular weight marker, W – whole cell lysate, S – spheroplast fraction (containing cytoplasmic contents and membranes), P – periplasmic fraction.

very stable at 37°C, with a T_m for unfolding of about 55°C. The mutant version that we used (LA57-N^{102LT}) contains a Leu to Ala alteration of amino acid 57 that dramatically reduces the stability of the folded structure. The LA57-N^{102LT} protein has a T_m of approximately 25°C, and is about 80% unfolded at 37°C and 60% unfolded at 30°C [27]. Further, the mutant protein has been shown to have a half-life of about 40 minutes in wild type *E. coli* strains at 37°C [27].

Localization of N^{102LT} and LA57-N^{102LT}

Plasmids pKL106 and pKL107 encoding LA57-N^{102LT}-FLAG or N^{102LT}-FLAG, respectively, were transformed into strains IM104 (wild type *secY*) or IM105 (*prlA4*). These strains contained deletion mutations in the *lon* and *degP* genes to limit proteolysis in both the cytoplasmic and periplasmic spaces. Following induction of the λ repressor fragment, whole cell lysates, spheroplasts, and periplasmic fractions were prepared from each strain. Samples were analyzed by Western blotting using antibodies directed against the FLAG epitope present at the carboxyl terminus of the λ repressor fragments.

According to our hypothesis, the largely unfolded nature of LA57-N^{102LT} should allow SecB to bind, resulting in targeting of LA57-N^{102LT} to translocase. In the *secY* wild type strain, proofreading by SecE/Y would block export of

LA57-N^{102LT}, while in the *prlA4* strain, the PrlA4 suppressor would allow export of a portion of LA57-N^{102LT} to the periplasm. This was not the result we observed (Fig. 1). No LA57-N^{102LT} was detected in the periplasm, even in the *prlA4* strain, indicating that export did not occur to any significant extent. To ensure that all periplasmic contents were released during the spheroplast preparation, the blots were stripped of FLAG antibody and reprobed with antibody directed against MalE, a periplasmic binding protein. All detectable MalE was present in the periplasmic fractions (data not shown), demonstrating that complete release of the periplasmic contents had been attained. Therefore, there was no detectable export of LA57-N^{102LT} in the *prlA4* strain.

There were two reasonable explanations for this unexpected finding; 1) an unfolded state is not sufficient for SecB binding, or 2) SecB binding is not sufficient to promote export in a *prl* suppressor strain. To distinguish between these possibilities, we examined whether SecB was able to bind LA57-N^{102LT} using two different methods to identify interactions. The first approach was co-immunoprecipitation of LA57-N^{102LT}-SecB complexes, the second was an *in vitro* protease protection assay.

Co-immunoprecipitation of SecB complexes

Co-immunoprecipitations were performed using whole cell lysates of strains induced for expression of λ repressor. Immunoprecipitations were performed as described using antibodies directed either against SecB or against the His tag on the λ repressor. Following the immunoprecipitation reaction, samples were analyzed by Western blotting using the opposite antibody, that is, samples that had been immunoprecipitated with anti-SecB were examined with anti-His while those that had been precipitated with anti-His were probed with anti-SecB. In addition, as a positive control, the interaction of SecB with the secretory protein LamB was examined using anti-LamB antibodies. While an interaction between LamB and SecB was clearly seen (Fig. 2c), no interaction was observed between SecB and either N^{102LT} or LA57-N^{102LT} (Fig. 2a and 2b). This was true regardless of whether the precipitating antibody was directed against SecB or the His tag. The wild type N^{102LT} was not expected to interact with SecB as it would fold very rapidly and stably; it was more surprising that no interaction was detected between SecB and the destabilized LA57-N^{102LT}. This result implied that the unfolded nature of LA57-N^{102LT} was not sufficient for SecB binding.

Protease protection assays

To substantiate the results observed by co-immunoprecipitation, an *in vitro* protease protection assay was employed. SecB has a proteolytic-sensitive domain that is cleaved by proteinase K in a limited proteolysis reaction. When substrate is bound to SecB, the conformation is al-




Figure 2
Immunoprecipitations of SecB complexes A. Precipitation was performed with antibody directed against SecB, followed by immunoblotting using antibody against the His tag on the λ repressor fragments. B. Precipitating antibody was directed against the His tag, immunoblotting utilized the anti-SecB antibody. C. Precipitation was carried out with antibody against LamB, anti-SecB was used for immunoblotting. In all gels, samples were as follows: lanes 1–4 – whole cell lysates prior to immunoprecipitation, lanes 5–8 – immunoprecipitated material; lanes 1 and 5 – $N^{102LT}/prlA4$, lanes 2 and 6 – $LA57-N^{102LT}/prlA4$, lanes 3 and 7 – $N^{102LT}/prlA^+$, lanes 4 and 8 – $LA57-N^{102LT}/prlA^+$, lane 9 in gel B – purified SecB.

tered such that the site is no longer protease accessible, rendering SecB protease resistant [28]. Thus, this assay can be used to detect binding of SecB to a substrate. Poly-L-lysine and small peptides are routinely used as substrates for this analysis as demonstrated in Fig. 3 (lanes 3 and 4). To determine whether a larger protein was also able to protect SecB, we used purified, urea-denatured proOmpA as a substrate. The proOmpA also was able to bind to and protect SecB (Fig. 3, lanes 9 and 10) although a much higher concentration of substrate was required to achieve 50% protection. To ensure that the observed protection was not due simply to the high protein concentration in the reaction, a non-secretory protein was used as a negative control. BSA was added to the same concentration or higher as proOmpA with no resultant protection of SecB (data not shown). Therefore, this assay reliably serves as an additional method to observe SecB-substrate interactions.

The λ repressor proteins were purified on a nickel affinity chromatography column by virtue of the His tag at the carboxyl terminus of the proteins. Each was assayed for




Figure 3
Protease protection assays Lane 1 – undigested SecB, lane 2 – SecB digested with proteinase K; lanes 3 through 10 – SecB was incubated with potential substrates at the indicated concentrations prior to proteinase K digestion; lane 3 – 20 nM poly-L-lysine, lane 4 – 150 nM poly-L-lysine; lane 5 – 150 nM N^{102LT} (wild type), lane 6 – 4 μ M N^{102LT} ; lane 7 – 150 nM $LA57-N^{102LT}$ (slow folding mutant), lane 8 – 4 μ M $LA57-N^{102LT}$; lane 9 – 150 nM proOmpA, lane 10 – 1.4 μ M proOmpA; lane 11 – proOmpA alone digested with proteinase K. Lower molecular weight band in lanes 6 and 8 is the λ repressor fragment.

protection of SecB at concentrations up to and exceeding that used for proOmpA. Neither N^{102LT} nor $LA57-N^{102LT}$ protected SecB from proteolysis, indicating that no binding occurred (Fig. 3, lanes 5–8). Although the mutant $LA57-N^{102LT}$ is predicted to be in an unfolded conformation in the bacterial cell, the protease protection assay was performed at 4°C. To verify that refolding of $LA57-N^{102LT}$ at this temperature was not interfering with interpretation of the results, we further tested the SecB binding activity by incubating $LA57-N^{102LT}$ in 8 M urea, then diluting it into the protection reaction, similar to the conditions used for proOmpA. Again, no protection was detected (data not shown). These results demonstrated that even when fully unfolded, $LA57-N^{102LT}$ was not a substrate for SecB binding.

Conclusions

The hypothesis driving the present studies was premised on the observation that *prl* suppressor strains are able to correctly identify secretory proteins, even in the absence of a signal sequence. It has been widely thought that this recognition was due to slow folding of secretory proteins in the cytoplasm, resulting in binding by SecB and subsequent targeting to translocase. While slow folding may be a necessary criterion for export, the data presented here indicate that an unfolded nature is not sufficient for SecB binding and targeting. This conclusion is based on failure of the $LA57-N^{102LT}$ protein to bind SecB either in vivo or in vitro. The in vivo results are founded both on the co-immunoprecipitation experiments and on the fact that no export of the protein was detected in a *prlA4* strain, while the in vitro results are based on the protease protection assays. Therefore, we conclude that secretory proteins must contain information, in addition to the signal sequence and slow folding characteristics, that targets them to the

secretory pathway or that cytoplasmic proteins contain information that prevents export even if the folding parameters are altered. Further studies are underway to identify such targeting sequences.

Methods

Bacterial strains and plasmids

All bacterial strains used were derivatives of *E. coli* K12 strain MC4100 [29]. IM104 is MC4100 *lamB14D lon::Tn10 degP::kan* and IM105 is IM104 *prlA4*. Plasmids pKL106 and pKL107 are pET11c (Novagen) derivatives carrying tandem copies of the λ repressor fragment (derived from plasmids pAD103 and pAD105, generous gifts from Alan Davidson, University of Toronto and Robert Sauer, MIT). In pKL106, the wild type λ repressor is tagged with the myc epitope and the LA57 λ repressor has the FLAG epitope. In pKL107, the wild type λ repressor contains the FLAG epitope and the LA57 mutant has the myc epitope. In all experiments, only antibodies to the FLAG epitope were used, therefore pKL106 resulted in detection of the mutant λ repressor and pKL107 was used to observe the wild type. Plasmids pIM101 and pIM102 were used in the co-immunoprecipitation assays and for purification of the λ repressor fragments. These plasmids are derivatives of pET11c that contain a single copy of the λ repressor, either wild type (pIM102) or LA57 (pIM101). The λ repressor inserts contain a FLAG tag at the carboxyl terminus followed by a hexahistidine motif.

Bacterial growth, induction and fractionations

Plasmid-containing bacteria were grown in LB [30] with ampicillin ($100 \mu\text{g ml}^{-1}$) at 30°C . Cells were induced for expression of the λ repressors at an $\text{OD}_{600} = 0.4-0.5$ by addition of 1 mM IPTG either for 30 minutes (spheroplast procedures) or for 3 hours (immunoprecipitation experiments).

Spheroplasts were prepared similarly to published protocols [31]. Briefly, 1 ml of bacterial cells was pelleted for 3 min at 16,000 rpm in an Eppendorf centrifuge. All subsequent steps were performed on ice. The cell pellet was resuspended in 0.5 ml spheroplast buffer [1 M sucrose, 25 mM TrisHCl (pH 8.0), 5 mM EDTA, and lysozyme ($50 \mu\text{g ml}^{-1}$)]. After incubation on ice for 12 min, MgCl_2 was added to a final concentration of 3 mM and incubation continued for an additional 5 min. The spheroplasts were pelleted by centrifugation at 16,000 rpm for 10 min at 4°C . The resultant supernatant contained the periplasmic contents. The pellet, which consisted of the membranes and cytoplasmic contents, was resuspended in 0.5 ml of spheroplast buffer. A parallel sample was prepared without the final centrifugation step, resulting in a whole cell lysate. All samples were precipitated with TCA and resuspended in gel loading buffer preparatory to electrophoresis.

Immunoblotting

Fractions were electrophoresed on 17% polyacrylamide gels and transferred to nitrocellulose. Immunoblotting was performed as described [32] using monoclonal antibody M2 directed against the FLAG epitope (Eastman Kodak) at a 1:600 dilution, or monoclonal antibody against MalE (Sigma) at a 1:500 dilution. When necessary, antibodies were stripped from the nitrocellulose by incubation in stripping buffer [1 M glycine (pH 2.2), 20 mM MgAc, 50 mM KCl] followed by immunoblot blocking solution.

Immunoprecipitations

Bacterial cells were induced for 3 hours for λ repressor expression as described above and harvested by French Press lysis. Lysates were immunoprecipitated with minor alterations to previous protocols [8]. Specifically, the IP buffer contained only 50 mM NaCl and incubation with the primary antibody was performed overnight at 4°C . Antibodies used were directed against the His epitope (monoclonal, Boehringer Mannheim), SecB (polyclonal, gift from William Wickner), or LamB (polyclonal, gift of Thomas Silhavy). Immune complexes were collected with Protein A agarose (Pierce), samples were electrophoresed on 15% polyacrylamide gels, and immunoblotting performed as described above. Following immunodetection, all blots were stripped of primary antibody and reprobed with the precipitating antibody to verify that precipitation had occurred.

Protease protection assays

SecB protease protection assays were performed as described [28], followed by electrophoresis on 15% polyacrylamide gels and detection by Coomassie Blue staining. The λ repressor fragments were purified by nickel NTA affinity chromatography (Qiagen).

Authors' contributions

Localization studies were performed by IM, immunoprecipitations and protease protection assays were carried out by MAS. AMF conceived of the study and participated in its design and coordination. The manuscript was written by AMF and edited jointly by all authors. All authors read and approved the final manuscript.

Acknowledgements

We are grateful to Kathy LaVoi for construction of pKL106 and pKL107. We thank Alan Davidson and Kevin Young for helpful discussion. This material is based upon work supported by, or in part by, the U.S. Army Research Office under contract/grant number DAAH04-96-1-0426 (G).

References

1. Danese PN, Silhavy TJ: **Targeting and assembly of periplasmic and outer-membrane proteins in *Escherichia coli***. *Annu Rev Genet* 1998, **32**:59-94
2. Duong F, Eichler J, Price A, Leonard MR, Wickner W: **Biogenesis of the gram-negative bacterial envelope**. *Cell* 1997, **91**:567-573

3. Fekkes P, Driessen AJ: **Protein targeting to the bacterial cytoplasmic membrane.** *Microbiol Mol Biol Rev* 1999, **63**:161-173
4. Manting EH, Driessen AJM: **Escherichia coli translocase: the unravelling of a molecular machine.** *Mol Microbiol* 2000, **37**:226-238
5. Derman AI, Puziss JW, Bassford PJ Jr, Beckwith J: **A signal sequence is not required for protein export in prlA mutants of Escherichia coli.** *EMBO J* 1993, **12**:879-888
6. Emr SD, Hanley-Way S, Silhavy TJ: **Suppressor mutations that restore export of a protein with a defective signal sequence.** *Cell* 1981, **23**:79-88
7. Fikes JD, Bassford PJ Jr: **Novel secA alleles improve export of maltose-binding protein synthesized with a defective signal peptide.** *J Bacteriol* 1989, **171**:402-409
8. Flower AM, Doebele RC, Silhavy TJ: **PrlA and PrlG suppressors reduce the requirement for signal sequence recognition.** *J Bacteriol* 1994, **176**:5607-5614
9. Bieker KL, Silhavy TJ: **The genetics of protein secretion in E. coli.** *Trends Genet* 1990, **6**:329-334
10. Schatz PJ, Beckwith J: **Genetic analysis of protein export in Escherichia coli.** *Annu Rev Genet* 1990, **24**:215-248
11. Bost S, Belin D: **prl mutations in the Escherichia coli secG gene.** *J Biol Chem* 1997, **272**:4087-4093
12. Osborne RS, Silhavy TJ: **PrlA suppressor mutations cluster in regions corresponding to three distinct topological domains.** *EMBO J* 1993, **12**:3391-3398
13. Prinz WA, Spiess C, Ehrmann M, Schierle C, Beckwith J: **Targeting of signal sequenceless proteins for export in Escherichia coli with altered protein translocase.** *EMBO J* 1996, **15**:5209-5217
14. Khisty VJ, Munske GR, Randall LL: **Mapping of the binding frame for the chaperone SecB within a natural ligand, galactose-binding protein.** *J Biol Chem* 1995, **270**:25920-25927
15. de Cock H, Overeem W, Tommassen J: **Biogenesis of outer membrane protein PhoE of Escherichia coli evidence for multiple SecB-binding sites in the mature portion of the PhoE protein.** *J Mol Biol* 1992, **224**:369-379
16. Gannon PM, Li P, Kumamoto CA: **The mature portion of Escherichia coli maltose-binding protein (MBP) determines the dependence of MBP on SecB for export.** *J Bacteriol* 1989, **171**:813-818
17. Randall LL, Topping TB, Hardy SJS: **No specific recognition of leader peptide by SecB, a chaperone involved in protein export.** *Science* 1990, **248**:860-863
18. Topping TB, Randall LL: **Determination of the binding frame within a physiological ligand for the chaperone SecB.** *Protein Sci* 1994, **3**:730-736
19. Hartl F-U, Lecker S, Schiebel E, Hendrick JP, Wickner W: **The binding cascade of SecB to SecA to SecY/E mediates preprotein targeting to the E. coli plasma membrane.** *Cell* 1990, **63**:269-279
20. Breukink E, Nouwen N, van Raalte A, Mizushima S, Tommassen J, de Kruijff B: **The C terminus of SecA is involved in both lipid binding and SecB binding.** *J Biol Chem* 1995, **270**:7902-7907
21. Cunningham K, Wickner W: **Specific recognition of the leader region of precursor proteins is required for the activation of translocation ATPase of Escherichia coli.** *Proc Natl Acad Sci USA* 1989, **86**:8630-8634
22. Kimura E, Akita M, Matsuyama S, Mizushima S: **Determination of a region in SecA that interacts with presecretory proteins in Escherichia coli.** *J Biol Chem* 1991, **266**:6600-6606
23. Lill R, Dowhan W, Wickner W: **The ATPase activity of SecA is regulated by acidic phospholipids, SecY, and the leader and mature portions of precursor proteins.** *Cell* 1990, **60**:271-280
24. Hardy SJS, Randall LL: **A kinetic partitioning model of selective binding of nonnative proteins by the bacterial chaperone SecB.** *Science* 1991, **251**:439-443
25. Fekkes P, den Blaauwen T, Driessen AJM: **Diffusion-limited interaction between unfolded polypeptides and the Escherichia coli chaperone SecB.** *Biochemistry* 1995, **34**:10078-10085
26. Kumamoto CA, Francetic O: **Highly selective binding of nascent polypeptides by an Escherichia coli chaperone protein in vivo.** *J Bacteriol* 1993, **175**:2184-2188
27. Parsell DA, Sauer RT: **The structural stability of a protein is an important determinant of its proteolytic susceptibility in Escherichia coli.** *J Biol Chem* 1989, **264**:7590-7595
28. Randall LL: **Peptide binding by chaperone SecB: implications for recognition of nonnative structure.** *Science* 1992, **257**:241-245
29. Casadaban MJ: **Transposition and fusion of the lac genes to selected promoters in Escherichia coli using bacteriophage lambda and mu.** *J Mol Biol* 1976, **104**:541-555
30. Silhavy TJ, Berman ML, Enquist LW: **Experiments with gene fusions.** Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press 1984
31. Thorstenson YR, Zhang Y, Olson PS, Mascarenhas D: **Leaderless polypeptides efficiently extracted from whole cells by osmotic shock.** *J Bacteriol* 1997, **179**:5333-5339
32. Harlow E, Lane D: **Antibodies A laboratory manual.** Cold Spring Harbor: Cold Spring Harbor Laboratory 1988

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright



BioMedcentral.com

Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>

editorial@biomedcentral.com